Literature DB >> 673990

Therapy of Candida peritonitis: penetration of amphotericin B into peritoneal fluid.

L R Peterson, R H Kelty, W H Hall, H J Votava.   

Abstract

Candida albicans peritonitis developed in a 48-year-old man with a perforated gastric ulcer who subsequently was treated with intravenous amphotericin B. The drug penetrated well into the inflamed peritoneal cavity and eradicated the organism from the peritoneal fluid. Nevertheless, at post-mortem, Candida organisms were demonstrated in a gall-bladder empyema and within the gall-bladder wall. Because intra-abdominal organs may be involved in Candida peritonitis, the use of high dose amphotericin B administered either intravenously, intraperitoneally, or both intravenously and intraperitoneally is recommended.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 673990      PMCID: PMC2425136          DOI: 10.1136/pgmj.54.631.340

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  7 in total

1.  Treatment of Candida peritonitis by peritoneal lavage with amphotericin B.

Authors:  R A Bortolussi; M R MacDonald; R M Bannatyne; G S Arbus
Journal:  J Pediatr       Date:  1975-12       Impact factor: 4.406

2.  OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.

Authors:  W R GREEN; J E BENNETT; R D GOOS
Journal:  Arch Ophthalmol       Date:  1965-06

Review 3.  Chemotherapy of systemic mycoses (second of two parts).

Authors:  J E Bennett
Journal:  N Engl J Med       Date:  1974-02-07       Impact factor: 91.245

4.  Candida peritonitis in a quadriplegic: treatment with amphotericin B.

Authors:  K O Reeves; A C Ripepi; R E Carter; T W Williams
Journal:  South Med J       Date:  1972-03       Impact factor: 0.954

5.  Peritonitis caused by candida albicans.

Authors:  C Montemartini; G Specchia; B Dander
Journal:  Digestion       Date:  1970       Impact factor: 3.216

6.  Candida peritonitis. Report of 22 cases and review of the English literature.

Authors:  A S Bayer; M J Blumenkrantz; J Z Montgomerie; J E Galpin; J W Coburn; L B Guze
Journal:  Am J Med       Date:  1976-12       Impact factor: 4.965

7.  Amphotericin B therapy in an anephric patient.

Authors:  H A Feldman; J D Hamilton; R A Gutman
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

  7 in total
  4 in total

Review 1.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

2.  Therapeutic Drug Monitoring of Amphotericin-B in Plasma and Peritoneal Fluid of Pediatric Patients after Liver Transplantation: A Case Series.

Authors:  Francesca Tortora; Luigi Dei Giudici; Raffaele Simeoli; Fabrizio Chiusolo; Sara Cairoli; Paola Bernaschi; Roberto Bianchi; Sergio Giuseppe Picardo; Carlo Dionisi Vici; Bianca Maria Goffredo
Journal:  Antibiotics (Basel)       Date:  2022-05-11

3.  Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

Authors:  M A Amantea; R A Bowden; A Forrest; P K Working; M S Newman; R D Mamelok
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Along came a spider: an unusual organism identified in a peritoneal dialysis patient, a case report and literature review.

Authors:  Victoria Jane Carnall; Stephanie Murdock; Cressida Auckland; Christopher J Mulgrew
Journal:  BMC Nephrol       Date:  2020-11-11       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.